This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Statement From IACP EVP/CEO David Miller, R.Ph. Regarding Congressman Markey's Bill

WASHINGTON, Nov. 8, 2012 /PRNewswire-USNewswire/ -- The International Academy of Compounding Pharmacists (IACP) has reviewed the legislation filed by Congressman Edward Markey in response to the meningitis outbreak that emanated from contaminated steroid injections prepared by New England Compounding Center, and we applaud the Congressman's efforts to ensure safety and advance quality in the compounding profession.  The nation's compounders provide a vital service to patients in need and the Congressman's legislation recognizes and protects this service.


As with any piece of complex legislation, there are provisions that we support and those that we do not.  Most notably, we support the preservation of state regulatory authority for traditional compounding pharmacy activities.  All boards of pharmacy must be adequately funded by state legislatures in a manner sufficient to hire trained/educated pharmacists to conduct regular inspections of all pharmacies.  Too many boards have been "de-funded" by the diversion of revenue from the Boards into the states' general funds, leaving administrative gaps.

Drug manufacturers are not compounders, and for that reason the IACP also supports ensuring that the FDA takes action against any business engaged in illegal drug manufacturing while still preserving the individual state's authority and right to govern the practice of compounding pharmacy. 

The IACP also supports the following provisions:
  • Allowing collaboration between the FDA and pharmacies to compound preparations to fulfill drug shortages or to protect public health. 
  • Providing for a process by which pharmacies may compound preparations to provide physicians, hospitals and clinical practice sites with medications necessary for administration to patients as part of their medical treatment. 
  • Ensuring that the FDA has clear authority to inspect any compounding pharmacy to assure that the storage and handling of medications are conducted in such a manner as to protect the health and safety of the public, although we would note that such authority already exists.
  • The continuation of the FDA "Do Not Compound" list of drugs that have been determined by the FDA to be clinically unsafe.  IACP believes this list must be created in collaboration with experts from the pharmacy and medical practice communities as the current FDA list was created without any review or input from practitioners. 

While we support the concept of actively reporting adverse reactions to compounded preparations to the FDA's MedWatch program, the existing system is designed in such a manner as to actually impede pharmacists' participation.  This will require more collaboration between the FDA and compounding pharmacists before it can be implemented. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.75 -1.10%
FB $117.53 0.69%
GOOG $693.00 0.29%
TSLA $240.75 -2.80%
YHOO $36.61 0.06%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs